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ABSTRACT 
 
Introduction:  Fracture healing is a complex process that is responsible 
for forming a fracture callus to stabilize the site of injury while producing new 
bone.  Delayed fracture healing or the development of non-union as a result of 
failed fracture healing is a major clinical concern effecting ~10% of all treated 
fractures.  Recent studies have shown that RAP-661, an antagonist of Bone 
Morphogenetic Proteins (BMP) 2 and BMP-4 binding to its receptor BMPR-1A 
has shown anabolic efficacy in treating bone loss associated with osteoporosis.  
The purpose of this study was to assess the effectiveness of the RAP-661 
protein as a therapeutic agent to improve fracture healing. 
Materials and Methods:  34 C57/B6 mice received unilateral mid-shaft 
transverse right femur fractures.  Three study groups used:  Vehicle Treated 
Control (10 mM Tris-Buffered Saline) and RAP-661 in 10 mM TBS either where 
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the drug treatment was administered continuously over the 35 days of the study 
or administered with a delayed treatment beginning 14 day after fracture.  Both 
drug and vehicle were administered via intraperitoneal injection twice per week.  
RAP-661 was administered at 10 mg/kg for each injection.  The mice were 
terminally harvested at 35 days.  The harvested femora were then tested via 
microCT analysis for material and structural properties and by mechanical testing 
for strength and torsional stiffness and rigidity.  
Results:  MicroCT testing showed that both drug groups had increased bone 
volume and bone volume percentage.  Mechanical testing however, showed that 
the control group was significantly stronger based on its maximal torque to failure 
than both either drug treatment group.  Although not significant, the 35 day delay 
group showed comparable stiffness and rigidity to the control and trended toward 
higher values compared to the 35 day continuous group. 
Conclusion:  Although both drugs groups had increased total mineral density 
and percentage bone volume, they both had significantly lower maximal torque to 
failure when compared to the control.  This discordance indicates that while the 
RAP-661 improves overall bone accumulation, it is effecting the structural 
integrity of bone bridging in some manner that compromise the regain of the 
bone’s normal mechanical strength.  Further research will be needed to resolve 
the mechanism(s) behind this phenomenon.  These results indicate that RAP-
661 does not show therapeutic efficacy in promoting fracture healing. 
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INTRODUCTION 
 
Fracture Overview 
Fractures are among the most common large organ traumatic injuries.  
Fracture incidence is also increasing due to osteoporosis related fractures in the 
growing elderly population in the U.S.  Fracture are such a common injury that a 
therapy developed to decrease healing time and increase bone strength after 
injury would have wide spread benefits in a large and growing population.  
Osteoporosis is the most common bone disease in the U.S. with an estimated 10 
million Americans over the age of 50 inflicted with the disease and another 34 
million at risk each year.  An estimated half of all women over the age of 50 and 
one quarter of all men will experience a fracture due to osteoporosis.  In 2002, 
the cost of care for osteoporotic fractures was estimated to be between $12.2 to 
$17.9 billion each year (USDHHS Office of the Surgeon General, 2004).  The 
cost of care and incidences of osteoporotic related fractures are increasing each 
year as the growing population continues to age.  It is estimated that by 2025 
osteoporosis will be responsible for almost three million fractures and incur $25.3 
billion of costs each year (National Osteoporosis Foundation, 2013) 
 
Endochondral and Intramembranous Ossification 
 To better understand the mechanism in which a fracture is healed it is 
important to review the two processes by which embryonic bone is formed and 
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how bones grow along the growth plate.  These two important processes are 
endochondral and intramembranous ossification.  The two processes differ in the 
fact that endochondral ossification requires a cartilage intermediate that is then 
replaced with bone while intramembranous ossification involves the direct 
conversion of mesenchymal cells into bone (Gilbert, 2000) 
 Endochondral bone formation, also known as endochondral ossification, is 
the process by which the bones of the axial and appendicular skeleton and lower 
mandible are initially formed.  This process is also responsible for the elongation 
growth of long bones.  Unlike intramembranous ossification, existing cartilage 
must be present for endochondral ossification to occur.  The initial cartilage is 
formed through the condensation of mesenchymal cells, when then differentiates 
into chondrocytes.  The chondrocytes undergo proliferation, hypertrophy, and 
secrete a specialized extracellular matrix to increase the length and size of the 
cartilage model (Mackie et al., 2008).  Ossification starts at the primary and 
secondary centers of ossification located in the center of the diaphysis (primary 
center) and at each epiphysis (secondary centers).  At these sites the cartilage 
matrix becomes mineralized and blood vessels invade the cartilage model 
bringing in osteoprogenitor cells and osteoclasts.  The chondrocyte in these 
mineralized areas will undergo programmed cell death leaving behind their initial 
scaffold of mineralized tissue.  As this process takes place, blood vessels will 
grow into these areas of mineralization, bringing mesenchymal stem cells with 
them.  These stem cells will then differentiate into osteoprogenitor cells that will 
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then undergo differentiation into osteoblasts on these scaffolds and begin to 
deposit bone matrix while in other areas the osteoclasts will also remove some of 
the areas of mineralized cartilage matrix (Mackie et al., 2008). 
 Intramembranous ossification is responsible for the formation of the flat 
bones of the skull.  The process of intramembranous ossification begins with the 
proliferation and condensation of mesenchymal cells into compact nodules.  
From these nodules, the mesenchymal cells differentiate into osteoblasts as well 
as capillaries (Gilbert, 2000).  The osteoblasts secrete an osteoid matrix capable 
of binding calcium salts allowing the osteoid to become calcified into bone.  
Through this process some of the osteoblasts secreting the osteoid matrix 
become trapped within their own secretions and then become osteocytes.  From 
the site of ossification, bony spicules radiate out which then become surrounded 
by mesenchymal cells that eventually form the periosteum (Gilbert, 2000).  The 
periosteum is the membrane that surrounds the bone.  Cells lining the inner part 
of the periosteum become osteoblasts and continue to secrete osteoid matrix 
leading the many layers of bone formation (Gilbert, 2000)  
 
Fracture Healing 
 Fractures are a break in a bone that results from a force introduced to the 
bone that exceeds the bones strength or ability to absorb the force.  Bones can 
become more susceptible to fractures from conditions such as osteoporosis that 
weaken the strength and integrity of the bone.  Following a fracture to the bone, 
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the bone heals in two distinct processes.  These processes are primary fracture 
healing and secondary fracture healing.  Primary fracture healing is the process 
first responsible for uniting the separated broken cortex back together (Einhorn, 
1998).   
 For primary facture healing to occur, the cortices of both sides of the bone 
must join to reestablish mechanical continuity.  Osteoclasts on one side of the 
fracture undergo a tunneling resorptive response that result in the formation of 
new Haversian systems, which provide routes for blood vessels to penetrate the 
site of injury (Einhorn, 1998).  These blood vessels bring the necessary 
osteoprogenitor cells crucial for the formation and healing of the bone.  This 
process of primary fracture healing can only occur if the fragments of the fracture 
are restored anatomically and if the fracture site is stabilized by rigid internal 
fixation (Einhorn, 1998).   
 During secondary fracture healing, both uncommitted osteoprogenitor 
cells and osteoblasts contribute to the fracture healing in a process paralleling 
both embryonic intramembranous ossification and endochondral bone formation.  
Secondary fracture healing is responsible for initially forming a callus to stabilize 
the fracture fragments.  The periosteum and external soft tissues both play 
crucial roles in the process.  Secondary fracture healing seems to be dependent 
on mechanical factors and is inhibited by rigid immobilization (Einhorn, 1998).  
During secondary fracture healing intramembranous ossification is seen on the 
proximal and distal sides away from the fracture site while endochondral 
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ossification is seen adjacent to the fracture site.  The intramembranous 
ossification located further from the fracture site results in a “hard callus” which is 
the result of direct bone formation.  The endochondral ossification forms a “soft 
callus” as a result of the early formation of cartilage which is later replaced by 
bone (Einhorn, 1998).  The external soft tissue response also helps stabilize the 
bone fragments through endochondral ossification.  This whole process is crucial 
for the rapid closure of the gaps produced by the fracture (Einhorn, 1998). 
 Fracture healing proceeds through 5 stages; hematoma formation and 
inflammation, angiogenesis and cartilage formation, cartilage calcification, 
cartilage removal and bone formation, and longer term bone remodeling 
(Einhorn, 1998).  The formation of the hematoma and inflammation has been 
implicated in serving as source of signaling molecules which are important to 
initiate the cascade of steps in bone healing and formation.  During the first 7 to 
10 days woven bone appears opposed to the cortex near the fracture site 
resulting from intramembranous ossification.  Adjacent to the fracture site, 
cartilage appears as result of the beginnings of endochondral ossification from 
the periosteum and external soft tissues (Einhorn, 1998).  Starting after 10 days, 
the callus can be differentiated into the “hard” and “soft” callus.  The callus tissue 
is formed primarily of cartilage, that then undergoes hypertrophic progression to 
a mineralized stage, that then undergoes vascular invasion and resorption and 
replacement by bone.  At the “hard” callus section intramembranous ossification 
is occurring further from the fracture site and endochondral ossification is 
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occurring at the “soft” callus section.  As the callus becomes fully mineralized 
more bone is created and the callus begins to undergo remodeling by 
osteoclasts.  The bone is reshaped to its original structure with defined cortices 
and a new medullary space through a prolonged period of coupled remodeling 
(Gerstenfeld et al., 2003).  Coupled remodeling is the result of the relationship 
between osteoblasts and osteoclasts.  It depends on the anabolic rates of 
primary and secondary bone formation, as well as calcified cartilage resorption 
and primary bone remodeling (Gerstenfeld et al., 2005). 
 
Bone Morphogenetic Proteins 
Bone morphogenetic proteins (BMPs) are a group of growth factors that 
belong to the transforming growth factor-β (TGF-β) family.  They were originally 
discovered as factors that could induce bone and cartilage formation when 
implanted at ectopic sites (Miyazono et al., 2009).  BMPs have also been 
implicated in a number of biological activities in many different tissues and cell 
types.  Dysfunctions in BMP pathways lead to many clinical disorders including 
vascular and skeletal diseases as well as cancer (Miyazono et al., 2009).   
While there are many BMPs, for this study the focus will be on BMP-2 and 
BMP-4.  BMP-2 and BMP-4 are closely related and share 83% of their amino 
acid sequence (Kawabata et al., 1998).  BMP-2 and BMP-4 have been shown to 
be the stronger initiators of alkaline phosphatase activity and mesenchymal 
progenitor differentiation into osteoblasts (Miyazono et al., 2009).  Both BMPs 
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have a wide range of biological activities in vivo as well as during embryonic 
development.  Knockout of BMP-2, BMP-4, and bone morphogenetic protein 
receptor Type 1A (BMPR-1A) in a mouse model leads to embryonic death before 
bone development (Kamiya et al., 2008).  Deficiency of BMP-2 in a mouse model 
has also shown that BMP-2 is necessary for the initiation of fracture healing.  
Mice lacking BMP-2 in their bones are unable to resolve spontaneous fractures 
and do not experience the earliest steps in fracture healing despite other 
osteogenic stimuli still being present (Tsuji et al., 2006).  
Members of the TGF-β family bind two types of serine-threonine kinase 
receptors, type I and type II (Miyazono et al., 2009).  BMPs can bind to both 
types independently, however when both types are present binding affinity 
increases drastically (Kawabata, 1998).  Once a BMP has bound to a heterotypic 
receptor complex, the type II receptor will phosphorylate the type I receptor, 
which will in turn phosphorylate its intercellular second signal SMAD.  The 
activated SMAD will then form a complex with another SMAD (Miyazono et al., 
1998).  Once the SMAD complex has been bound, the complex translocates to 
the nucleus where it carries out its biological effects by regulating the 
transcription of target genes by interacting with different transcription factors, 
activators, and repressors (Miyazono et al., 1998). 
Although much of the signaling involved in osteogenesis is becoming 
better understood, much is still not clear.  The mechanism by which BMP 
signaling in osteoblasts contributes to skeletogenesis is not fully understood 
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(Kamiya et al., 1998).  Bone mass is determined by the relationship between 
bone formation and resorption.  BMPs have been shown to play a role in both 
processes.  However, the extent and to what degree BMPs have in each process 
is not clear.  Loss of BMP signaling decreased bone volume in young mice, but 
increased bone mass in old mice (Kamiya et al., 1998).  BMPR-1A deficient 
osteoblasts showed decreased osteoclastogenesis in mice (Kamiya et al., 1998).  
This implicates that by blocking that pathway, osteoclastogenesis was decreased 
which leads to fewer osteoclasts and decreased bone resorption.   
 
Current Fracture Therapies 
 Currently there are a number of drug therapies approved for the treatment 
of osteoporosis.  Bone remodeling is balanced by bone formation by osteoblasts 
and bone resorption by osteoclasts.  These therapeutic agents follow 2 modes of 
action.  They can act as an anti-resorptive agent or an anabolic agent.  The anti-
resorptive agents act by reducing osteoclastic activity.  Bone resorption rates are 
decreased by reducing the catabolic effects of osteoclasts in osteoporosis 
patients. There is concern that prolonged inhibition of osteoclast activity and their 
role in repairing microdamage and other normal processes would be impeded 
and lead to eventual bone weakening (Pearsall et al., 2008). Anabolic agents act 
by increasing osteoblast-mediated bone formation and provide an attractive 
alternate therapy. 
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 Bisphosphonates were the first anti-catabolic therapy that were approved 
and are the most widely and regularly used therapies for osteoporosis.  
Bisphosphonates act by inhibiting osteoclasts function, thereby inhibiting bone 
resorption which leads to an increase in bone mass due to refilling of the 
remodeling space and an increase in mineralized tissue density.  
Bisphosphonates bind to bone mineral with high affinity which allows for a high 
degree of organ specificity (Khosla et al., 2012).  After binding to the bone, the 
bisphosphonates are taken up by osteoclasts.  Once inside the osteoclasts, the 
bisphosphonate blocks specific metabolic pathways that are needed for the 
osteoclasts to function which disrupts cellular function and promotes apoptosis 
(Khosla et al., 2012).  In women, bone remodeling rates increase by double 
within 12 months of menopause, triple by the age of 60, and remain elevated in 
untreated osteoporosis patients (Khosla et al., 2012).  Administration of 
bisphosphonates reduces the rate of bone remodeling associated with 
microdamage repair.  Bisphosphonates are able to induce their therapeutic effect 
by inhibiting osteoclasts and decrease fracture incidences in osteoporosis 
patients.  Experimental studies have shown that bisphosphonate administration 
results in larger and stronger calluses, delayed remodeling, and no evidence of 
delayed healing (Larsson et al., 2012).  Bisphosphonates have been associated 
with some negative side effects but the rare rate of their occurrence does not 
outweigh the therapeutic effects they provide.  Possible negative side effects that 
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have been implicated with bisphosphonates include osteonecrosis of the jaw, 
atypical femur fractures, and atrial fibrillation (Khosla et al., 2012). 
 An alternate therapy that closely mirrors the mechanism by which 
bisphosphonates work to help osteoporosis patients is the use of bacillus 
fermented antlers.  Antlers have been used throughout history for its claimed 
medicinal and therapeutic properties.  Use of bacillus fermented antlers has 
shown to inhibit osteoclast differentiation and osteoclast regulated bone 
resorption (Choi et al., 2013).  Addition of the fermentation to the antler has 
shown to increase its osteogenic properties (Choi et al., 2013). 
 Receptor activator of NF kappa B ligand (RANKL) inhibitors have recently 
been developed as a possible treatment for osteoporosis.  RANKL inhibitors work 
by inhibiting osteoclasts precursor cells into osteoclasts (Larsson et al., 2012).  
When compared with the bisphosphonate alendronate, RANKL inhibitor 
denosumab produced very similar results on fracture healing.  Both drug groups 
showed increased callus volume, callus cross-sectional area, and increased 
mineral density when compared with the controls (Gerstenfeld et al., 2008).  Both 
groups also showed increased callus strength under mechanical testing, but it is 
important to note that most of the RANKL denosumab group fractures occurred 
outside the callus tissue indicating increased callus strength over the 
bisphosphonate alendronate group (Gerstenfeld et al, 2008). 
  Parathyroid hormone (PTH) has also been extensively researched 
a possible osteoporosis therapy.  Anabolic drugs exert their effects by positively 
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enhancing bone formation, instead of having a negative effect on osteoclast 
activity like all of the other treatments discussed so far.  The positive effects of 
anabolic therapy are an attractive possibility for fracture healing therapies.  The 
effects of PTH vary depending on the administration regimen.  When 
administered continuously, bone resorption is increased due to an increase in 
osteoclastic activity.  When administered intermittently, bone formation is 
increased due to increased osteoblast activity (Larsson et al, 2012).  Studies 
have shown that PTH administration for fracture healing resulted in larger and 
mechanically stronger calluses in less time (Larsson et al., 2012).  A diagram of 
PTH and PTH-related protein effects on osteoblasts can be seen in figure 1.  
The drug used in this study, RAP-661, is a soluble receptor fusion protein 
consisting of the extracellular domain of the activin receptor-like kinase-3 (ALK-3) 
Type I receptor, also known as BMPR-1A, fused to a murine IgG2a antibody Fc 
region.  RAP-661 acts as an antagonist by binding BMP-2 and BMP-4 with high 
affinity and blocking their signaling through their BMPRs. 
 
Current Goals 
 The aim of the study was to investigate the therapeutic efficacy of RAP-
661 in improving fracture healing.  The growing incidences of fractures due to 
osteoporosis as well as the already high incidence rate of fractures in healthy 
individuals in the country could benefit immensely from a therapy that could 
increase bone strength post-fracture and decrease fracture healing time.  In 
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addition to the health benefits, the cost of care for osteoporosis related fractures 
could be decreased incrementally.  The main focus of this study was to assess 
the effect of the RAP-661 protein on both the regain of mineralized tissue and 
mechanical competency after fracture.  The effect of the RAP-661 protein on 
fracture healing was assessed through microCT analysis and mechanical testing. 
 
 
 
Figure 1.  Effects of PTH and PTHrP on osteoblasts and bone anabolism (Esbrit et al., 2013). 
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MATERIALS AND METHODS 
 
Study Design 
 All aspects of these animal studies was carried out under a protocol that 
has been approved by the Boston Institutional Animal Care and Use Committee 
and were conducted in conformity with all federal and USDA guidelines.  Male 
mice at sexual maturity between 10-12 weeks of age were used for these 
studies.  C57/B6 mice were ordered from Jackson Laboratories, Bar Harbor, ME 
and were shipped directly to Boston University Laboratory Animal Science 
Center (LASC), Boston, MA.  All of the mice were housed at the LASC for the 
duration of the study as well as an additional 3 days when first shipped for 
acclimation to the facilities.   
 Three study groups used for the study were:  The vehicle treated control 
group (10 mM Tris-Buffered Saline), the continuous group that was administered 
RAP-661 in 10 mM TBS continuously from time of fracture, and the delay group 
that was administered RAP-661 in 10 mM TBS continuously starting 14 days 
post fracture.  The three groups were terminally harvested at 35 days.  For the 
microCT analysis the 35 Day Delay group consisted of 12 mice, the 35 Day 
Continuous group consisted of 10 mice, and the 35 Day Control group consisted 
of 12 mice.  For mechanical testing the 35 Day Delay group consisted of 10 mice, 
the 35 Day Continuous group consisted of 8 mice, and the 35 Day Control 
consisted of 10 mice.    
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 Both drug and vehicle were administered via intraperitoneal injection twice 
per week.  RAP-661 was administered at 10mg/kg for each injection.  Prior to 
administration, all drugs were warmed to room temperature and administered via 
a 25-gauge needle. 
 
Surgery 
 Starting at Day 0 (day of surgery), all animals were subjected to a 
unilateral fracture in the right femur.  All fractures were produced with a modified 
device as described by (Marturano et al., 2008) of the original apparatus 
described by Bonnerans and Einhorn (1984).  A picture of the device can be 
seen in figure 1.  Prior to surgery each animal was anesthetized with isoflurane.  
After anesthization, the right rear leg was shaved and disinfected with povidone 
iodine skin disinfectant.  A median longitudinal skin incision was introduced over 
the distal femur.  A hole was created by inserting the stylette of a 25 gauge spinal 
needle though the trochlea of the femur.  The pin was inserted in a retrograde 
manner and anchored in the major trochanter with gentle rotation.  The stylette 
was cut at the condylar surface and buried by pushing it through the cartilage into 
the underlying subcondylar bone.  The incision was closed with one internal 
suture.  Unilateral fractures were produced in the mid-shaft of the right femur 
using the scaled down version of the apparatus described by Bonnarens and 
Einhorn, 1984.  Confirmation of the fracture location and quality was confirmed 
by X-ray analysis directly following the production of the unilateral fracture using 
 15 
a GenDex Dental X-ray machine.  All X-rays were developed right after pin 
insertion and fracture by a portable x-ray developer.  All fractures that were 
determined to be unsuitable for reasons such as non-medial fractures or were 
inconsistent with standardized criteria were not used for the study.  An example 
of X-ray image of a suitable mid-diaphysis fracture can be seen in figure 2. 
 After X-ray analysis, each animal was subjected to an ear-cut 
identification.  This was accomplished by punching a hole in either the right ear, 
left ear, both ears, or no ears.  0.5 mg/kg of Buprenex® (buprenorphine) was 
delivered subcutaneously for post-operative pain management.  Additionally, the 
anti-biotic Baytril® was administered at a dosage of 2.5 mg/kg and delivered 
subcutaneous at the time of surgery.  Each animal then received 0.5 mg/kg of 
buprenorphine analgesia every 12 hours for 24 hours post fracture as well as one 
dose at 48 hours. 
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Figure 2.  Device used to produce unilateral fractures in the mouse femurs. 
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Figure 3.  Example of a right femur mid-diaphysis fracture with 25-gauge spinal needle stylette 
present in the medullary canal (Sacks, 2007). 
 
Specimen Harvesting 
 At time of harvest (35days), all mice were euthanized by CO2 
asphyxiation followed by secondary euthanasia by cervical dislocation.  After 
euthanasia, all fractures were evaluated radiologically by use of a Faxitron X-ray 
system.  After X-ray, both the fractured femora as well as the contralateral 
femora were excised by disarticulation of the limbs.  After all surrounding soft 
tissue and skin was removed; the femur was wrapped in sterile isotonic saline 
soaked gauze, placed in a labeled test tube, and dropped into liquid nitrogen.  All 
samples were kept in the liquid nitrogen until all samples had been finished being 
harvested.  Once harvesting was completed, all samples were placed in a 
marked box which was then placed in a -20º C freezer. 
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Microcomputed Tomography 
 To determine mineralized tissue content and structure, calluses from the 
35 day time points were scanned at an isotropic voxel size of 12 m (70 kVp, 
114mA, 200ms integration time; CT 40, Scanco Medical, Bruttisellen, 
Switzerland).  All bones intended for scanning were transported from a -20º C 
freezer in the Boston University Orthopaedic Research Laboratory to a -20º C 
freezer in the Boston University Orthopaedic and Developmental Biomechanics 
Laboratory.   
 All bones were thawed at room temperature and then removed from the 
wrapping gauze.  Depending on the size of the bone and its callus, a piece of 
packing Styrofoam was cut to insert along with the bone to ensure the bone did 
not move during scanning.  The bone and the Styrofoam insert were placed 
vertically inside the microCT tube.  Multiple bones up to a maximum of 3 were 
able to be placed inside the microCT tube at a time.  Each bone was placed with 
its own Styrofoam insert and were only stacked vertically on top of each other.  
Once all of the bones were placed in the microCT tube, the tube was filled with 
PBS.  All air bubbles were removed and the top was covered by a piece of 
Parafilm (Alcan Packaging, Neenah, WI).  The area of interest to be scanned 
was manually selected.  The area was selected to only include the callus and a 
small area directly below and above callus to ensure the whole callus was 
included.  Scans were performed at a medium resolution (12 μm voxel size) at 70 
kVp, 114 μA, and 200 ms integration time. 
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 Following scanning, all of the tomograms were contoured manually to 
define the boundary of the callus and to exclude all cortical bone and the 
medullary canal.  To define the inclusion portion of the callus, a rough counter-
clockwise trace of the outline of the callus was performed and the computer 
program selected the exact outline.  To establish the exclusion portion of the 
callus, a clockwise trace of the cortical bone and medullary canal was preformed 
manually to exact boundaries without aid of the computer program.  Cortical 
bone was distinguished by its much denser white color towards the center of the 
callus and was excluded.  Pieces of cortical bone that did not correspond to the 
medullary canal were also excluded by additional manual contours for the slices 
that they appeared.  The area between the inclusion boundary and exclusion 
boundary was used to perform all computations by the program for all desired 
data.  A fixed global threshold corresponding to 45% of the attenuation of the 
mature cortical bone was applied (Morgan et al., 2009).  Once the volume of 
interest was defined, the tomograms for each bone were evaluated to determine 
total volume (TV), mineralized volume (BV), mineralized volume fraction (BV/TV), 
tissue mineral density (TMD), bone mineralized content (BMC, defined as BV * 
TMD), trabecular number (Tb.N), trabecular spacing (Tb.S), and trabecular 
thickness (Tb.Th). 
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Three-Dimensional Rendering 
 Following scanning, all of the tomograms were contoured manually to 
define the boundary of the callus and to exclude all cortical bone and the 
medullary canal.    Once contoured, the SCANCO computer #D viewer program 
was able to construct three dimensional images of the fracture callus. 
 
Mechanical Testing 
 All bones intended for mechanical testing were transported from a -20º C 
freezer in the Boston University Orthopaedic Research Laboratory to a -20º C 
freezer in the Boston University Orthopaedic and Developmental Biomechanics 
laboratory.  For these studies this set of bones was sequentially assayed by 
microCT and mechanical testing.  These bones were first scanned individually 
and were thawed during the scanning process.  Bones intended for mechanical 
testing were placed in the microCT tubes with a solution of 40% ethanol and 60% 
phosphate buffered saline (PBS).  Directly following scanning, each bone was 
wrapped in gauze soaked in the alcohol-saline solution to ensure the bone 
remained hydrated.  While the bone was wrapped, a clamp was attached to a 
clamp stand and a set of forceps were placed in the clamp.  The bone was then 
placed gently into the forceps ensuring not to clamp any of the callus.  Two 
aluminum end cubes (1 cm3) were placed on two over turned paper cups.   Next, 
another paper cup was cut to make a shallow cup.  Bosworth Fastray powder 
and Bosworth Fastray solvent were then mixed in the cup to create liquid 
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polymethylmethacrylate (PMMA).  The consistency of the liquid PMMA was 
made at a low viscosity to ensure full encapsulation of the end of the bone placed 
in the PMMA.  Using a pipette, the liquid PMMA was transferred from the cup to 
the cap intended for the bone to first be placed and filled to the top.  PMMA was 
transferred into the second cap but was only filled half way.  The bone was then 
lowered into the primary cap by loosening the clamp from the clamp stand and 
slowly moving the clamp flush against the stand until the tip of the bone was 
submerged in the PMMA and then retightening the clamp.  The bone was only 
lowered into the PMMA close to the callus but never made contact with the 
callus.  After a few minutes, the top of the PMMA was hardened enough to place 
a small wrap of alcohol-saline soaked gauze around the bone.  The PMMA was 
hard enough to ensure no PMMA would be soaked up by the gauze.  The system 
was then allowed to sit for approximately 30 minutes for the PMMA to completely 
harden.  After the 30 minutes, both the cap with the bone and the half-filled cap 
were removed from the over-turned Dixie Cups.  All PMMA that accumulated 
from leaking at the end of the caps were removed to ensure the caps could lay 
flat on all 5 sides.  The caps were then placed flush in a L Beam and held in 
place by rubber bands.  Approximately 1 cm was left between the caps the whole 
system was clamped onto a clamp stand.  A second batch of liquid PMMA was 
made by the same procedure.  Using a pipette, the liquid PMMA was transferred 
to the half-filled cap and filled all the way.  Once completely filled, the caps were 
pushed towards each other slowly until the uncovered end of the bone was 
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submerged.  After approximately 5 minutes, another saline-alcohol gauze piece 
was wrapped around the bone.  The system was allowed to sit for another 30 
minutes to completely dry. 
 Immediately after the specimen was potted, the gauge length was 
measured by calipers.  The system was then placed into the clamps of the 
Instron 55MT Micro Torsion Testing System (Instron, Norwood, MA) ensuring not 
to introduce any stress on the callus.  Once placed into the machine the protocol 
was run to apply an angular rotation of 0.5 degrees/sec.  The Instron 55MT Micro 
Torsion Testing System plotted and collected the data which was then saved and 
exported for further evaluation.  The data of interest collected was maximal 
torque to failure, stiffness, and rigidity. 
 
Statistical Analysis 
 The effects of treatment on each group were determined using analysis of 
variance (ANOVA) with Tukey post hoc tests.  The significance level of 0.05 was 
used for all analyses. 
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RESULTS 
 
MicroCT Testing 
 A total of 34 bones were analyzed via microCT.  Of the 34 bones 12 were 
in the 35 day delayed drug treatment group, 10 were in the 35 day continuous 
drug treatment group, and 12 were in the 35 day control non-treated group.  A 
summary of the microCT data is presented in Table 1 and the comparisons 
between the three groups can be seen for each data category in figures 1-2.   
From the figures, some noticeable differences can be discerned.  For 
every category except for Total Volume (TV), the two treated drug groups are 
higher than the control.  For TV, the 35 Day Continuous group is the smallest, but 
when Bone Volume / Total Volume (BV%) is taken into account, we can see that 
the 35 Day Continuous group has the highest BV%.  Through analysis with one 
way analyses of variances (ANOVA), significant differences were found in BV%, 
total mineral density (TMD), bone mineral density (BMD), trabecular spacing 
(Tb.Sp), and trabecular Number (Tb.N) at an alpha level = .05.  There were no 
significant differences found in TV or bone volume (BV).  The 35 Day Delay 
treatment has the highest BV, followed by the 35 Day Continuous treatment, 
while the 35 Day Control showed the lowest values for these parameters.  For 
BV% we can see that 35 Day Continuous was the highest and was significantly 
different from both 35 Day Delay and 35 Day Control.  TV was the lowest in the 
35 Day Continuous treatment and could be a reason for the higher BV%.  For 
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TMD, the 35 Day Continuous treatment was the highest and was significantly 
different from both the 35 Day Delay and 35 Day Control treatments.  For Tb.N, 
the 35 Day Continuous treatment was the highest, followed by the 35 Day Delay 
treatment and then the 35 Day Control.  All treatments were significantly different 
from each other for Tb.N.  For Tb.Th, the 35 Day Continuous Treatment was the 
highest, followed the 35 Day Delay treatment and then the 35 Day Control.  The 
35 Day Continuous treatment was significantly different from the 35 Day Control 
group.  For Tb.Sp, the 35 Day Control group was the highest, followed by the 35 
Day Delay treatment and then the 35 Day Continuous treatment.  The 35 Day 
Control group was significantly different from both other groups. 
A three-dimensional rendering was created for a specimen in each of the 
groups.  These renderings can be seen in figures 3-5. 
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Table 1.  MicroCT Analysis 
Data shown are mean values ± SD. Significant differences between 35 Day Delay, 35 Day 
Continuous, or 35 Day Control are shown by 1, 2, or 3, respectively. 
 
 
 
 
 
 
 
 35 Day Delay 
35 Day 
Continuous 35 Day Control 
    
TV (mm
3
) 23.28 ± 12.08 16.39 ± 5.94 21.66 ± 8.12 
BV (mm
3
) 5.88 ± 2.52
 
5.77 ± 1.69
 
4.96 ± 1.74
 
BV% 27.90 ± 9.51
(2) 
36.10 ± 4.64
(1,3) 
23.60 ± 4.37
(2) 
TMD (mg HA/ccm) 449.42 ± 100.97
(2) 
544.92 ± 47.74
(1,3) 
389.36 ± 49.67
(2) 
BMD (mg HA/ccm) 1191.86 ± 23.72
(2) 
1215.32 ± 14.37
(1,3) 
1191.79 ± 26.72
(2) 
Tb.N (1/mm) 4.85 ± 0.72
(2,3) 
5.62 ± 0.52
(1,3) 
3.83 ± 0.54
(1,2) 
Tb.Th (mm) 0.11 ± 0.016
 
0.12 ± 0.016
(3) 
0.094 ± 0.012
(2) 
Tb.Sp (mm) 0.22 ± 0.035
(3) 
0.18 ± 0.021
(3) 
0.27 ± 0.037
(1,2) 
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Fig. 4.  Graphical analysis of TV, BV, BV%, BMD, and TMD. 
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Fig. 5.  Graphical analysis of Tb.N, Tb.Th, and Tb.Sp. 
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Figure 6.  Three-dimensional rendering of a sample in the 35 Day Delay group. 
 
 
Figure 7.  Three-dimensional rendering of a sample in the 35 Day Continuous group. 
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Figure 8.  Three-dimensional rendering of a sample in the 35 Day Control. 
 
Mechanical Testing 
 A total of 28 bones were analyzed via mechanical testing.  Of the 28 
bones 10 were in the 35 day delayed drug treatment group, 8 were in the 35 day 
continuous drug treatment group, and 10 were in the 35 day control non-treated 
group.  Two bones in the 35 day delayed drug treatment group, two bones in 35 
day continuous treatment group were broken, and two bones in the 35 day 
control group were broken and could not be used for mechanical testing from the 
original group of bones that were scanned via microCT.   A summary of the 
mechanical testing data is presented in Table 2 and the comparisons between 
the three groups can be seen for each data category in figure 3.   
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 The 35 Day Control had the highest max torque and was significantly 
different than both of the treated groups.  The 35 Day control also had the 
highest stiffness and rigidity, followed by the 35 Day Delay group and then the 35 
Day Continuous Group.  Differences in stiffness and rigidity were not significant. 
 
Table 2.  Mechanical Testing Data 
Data shown are mean values ± SD. Significant differences between 35 Day Delay, 35 Day 
Continuous, or 35 Day Control are shown by 1, 2, or 3, respectively. 
 
 
 
 
 
 
 
 35 Day Delay 
35 Day 
Continuous 35 Day Control 
    
Max Torque (N●mm)  0.023 ± 0.007
(3) 
0.024 ± 0.006
(3) 
0.039 ± 0.007
(1,2) 
Stiffness (Nm/rad) 0.478 ± 0.170
 
0.381 ± 0.091
 
.494 ± 0.135
 
Rigidity (N/rad) 0.109 ± 0.056
 
0.065 ± 0.018
 
.114 ± 0.056
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Fig. 9.  Graphical analysis of Max Torque, Stiffness, and Rigidity. 
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Discussion 
 
 The primary goal of fracture healing therapies is to increase fracture callus 
strength and decrease fracture healing time.  Development of such therapies 
would address a major clinical problem that the US is encountering with 
increased frequency due to the increasing number of osteoporosis related 
fractures.  The purpose of this study was to evaluate the efficacy of RAP-661, an 
antagonist that binds BMP-2 and BMP-4 and blocks their pathways, as a 
possible drug therapy for fracture healing.  Optimal fracture healing occurs when 
the structural integrity to the injured bone has been reestablished so that it may 
again experience stresses without incurring further damage.  The anti-
resorptive/anti-catabolic therapies that have been on the market for years for 
osteoporosis have shown great therapeutic effects however; very little 
investigation has been done on bone healing (Larsson, 2012).  In this regard, 
studies have been examining a number of anabolic therapies including PTH and 
anti-sost therapies (Ke et al., 2012, Axelrad et al, 2007). 
 Our results showed that continuous drug treatment lead to a significantly 
smaller overall callus volume, while delaying the treatment lead to overall callus 
sizes comparable to the controls.  Interestingly, the overall bone volume in both 
drug treatment groups was greater.  The greater overall BV for both treatment 
groups lead to the continuous treatment group having the highest mineral density 
and highest BV%.  The fact that the BV% of the 35 Day Continuous was 
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significantly different than the other two groups could be explained by two 
reasons.  The continuous treatment had the smallest TV, so in comparison to BV 
the ratio would lead to a higher BV%.  The continuous treatment could also have 
led to a greater amount of mineralized tissue.  The smaller TV in the 35 Day 
Continuous group compared to the other groups can also be seen in the three 
dimensional renderings in figures 3-5. 
The increased BV and BV% in both treated groups compared to the 
control group were consistent with our original expectation based on results seen 
when osteoporotic animals had been treated with the drug.  These results further 
lead us to initially speculate that the strength of the callus would also be 
increased, however this is not what was observed.  From the mechanical test 
data, we observed that the control experienced almost twice the max torque than 
both of the treated groups.  This observation illustrates a large discordance 
between the two sets of data, which has not been previously observed in other 
pharmalogical studies, in which we had always observed a strong correlation 
between both BMD and BV% and mechanical strength (Morgan et al., 2009).  
This discordance indicates that even though there was increased BV and BV%, 
the increase in mineralized tissue did not correlate to a stronger callus. 
Since the structural bridging of the external cortices over the callus is a 
major element in the regain in mechanical strength, a possible explanation for 
this phenomenon must be related with the structural elements of the callus.  The 
structural failure of the callus could only be explained by a failure of bridging.  A 
 34 
failure of bridging could explain the lower max torques observed and still allow for 
increased BV and BV%.  The increased BV could have just been in the 
surrounding callus but not contribute to the bridging of the fracture site.  Other 
possible explanations could be decreased or lack of cortical bone or decreased 
cross-sectional callus area.  While these are possible explanations, further 
evaluation must be done to determine the mechanism behind this observation.  
While not significant, we observed a higher stiffness and rigidity in the 35 
Day Delayed group compared to the 35 Day Continuous group.  This could 
indicate that by delaying the treatment, the callus was able to establish an initial 
effort to structurally repair the callus.  
When compared to other treatments, RAP-661 does not seem like a 
favorable choice as a therapy for fracture healing.   These data also suggest that 
if the drug was being used as an anti-osteoporosis therapy, its discontinuation 
would have to be considered in the case of a fracture injury, since their fracture 
healing would be impaired.   
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Conclusion 
 
 The purpose of this study was to assess the effectiveness of the RAP-661 
protein as a therapeutic agent for fracture healing.  C57/B6 mice had transverse 
fractures produced in the right femora and were administered either RAP-661 
continuously, RAP-661 delayed, or PBS (control) following the fracture.  The 
animals were harvested at 7, 14, 21, or 35 days post fracture.  The femora were 
analyzed by microCT and torsion testing.  Results showed that at the 35 day time 
point the two drug groups showed increased BV% but decreased mechanical 
strength compared to the control.  The 35 Day Delay group showed in 
incrementally larger max torque, stiffness, and rigidity which could indicate by 
delaying administration of the RAP-661 an initial bridging of the callus could 
occur, increasing mechanical strength.  The discordance between the increased 
mineralized tissue and decreased mechanical strength will require further 
research.  Further research using histology will be very helpful in elucidating what 
could be leading to the weaker calluses, regardless of the increased mineralized 
tissue.  In the future, long term studies will need to be conducted to further our 
understanding of the mechanism that RAP-661 is increasing callus size and 
mineralized tissue without increasing callus strength.  In the current short-term 
study, RAP-661 does not look like viable osteoporosis or fracture healing therapy 
due to its negative effects on callus strength. 
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